David M. Ellison

800 total citations
7 papers, 173 citations indexed

About

David M. Ellison is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, David M. Ellison has authored 7 papers receiving a total of 173 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Epidemiology and 3 papers in Molecular Biology. Recurrent topics in David M. Ellison's work include Nonmelanoma Skin Cancer Studies (3 papers), CAR-T cell therapy research (2 papers) and Cancer therapeutics and mechanisms (1 paper). David M. Ellison is often cited by papers focused on Nonmelanoma Skin Cancer Studies (3 papers), CAR-T cell therapy research (2 papers) and Cancer therapeutics and mechanisms (1 paper). David M. Ellison collaborates with scholars based in United States, Canada and India. David M. Ellison's co-authors include RJ Kurlander, Ramaswamy Govindan, Bruce E. Johnson, Joe Stephenson, Keith D. Eaton, Mark M. Awad, Mark A. Socinski, Holger Fritsch, Daniel S. Bradford and Leena Gandhi and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Annals of Oncology.

In The Last Decade

David M. Ellison

7 papers receiving 162 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David M. Ellison United States 5 71 61 54 51 21 7 173
Louis Marois Canada 8 95 1.3× 110 1.8× 37 0.7× 27 0.5× 14 0.7× 16 237
Angelika Stein Germany 6 94 1.3× 95 1.6× 19 0.4× 39 0.8× 18 0.9× 9 213
Jordi Milá Spain 11 56 0.8× 113 1.9× 42 0.8× 43 0.8× 4 0.2× 17 244
Yasutaka Okita Japan 8 59 0.8× 36 0.6× 7 0.1× 35 0.7× 22 1.0× 20 152
Tassja J. Spindler United States 6 96 1.4× 28 0.5× 10 0.2× 52 1.0× 16 0.8× 10 192
Matthew W. Anderson United States 7 72 1.0× 168 2.8× 24 0.4× 36 0.7× 28 1.3× 12 281
Nancy L. Samberg United States 7 66 0.9× 72 1.2× 10 0.2× 30 0.6× 35 1.7× 15 163
Lorien Nassi United States 4 79 1.1× 119 2.0× 11 0.2× 18 0.4× 21 1.0× 9 204
Y-L. Choi South Korea 5 66 0.9× 25 0.4× 8 0.1× 64 1.3× 51 2.4× 7 265
Stefano Vergani United States 9 59 0.8× 125 2.0× 27 0.5× 38 0.7× 4 0.2× 19 202

Countries citing papers authored by David M. Ellison

Since Specialization
Citations

This map shows the geographic impact of David M. Ellison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Ellison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Ellison more than expected).

Fields of papers citing papers by David M. Ellison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Ellison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Ellison. The network helps show where David M. Ellison may publish in the future.

Co-authorship network of co-authors of David M. Ellison

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Ellison. A scholar is included among the top collaborators of David M. Ellison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Ellison. David M. Ellison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Park, Soo Jung, David M. Ellison, Ryan Weight, et al.. (2025). CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma. Future Oncology. 21(4). 431–436. 1 indexed citations
2.
3.
Ganz, Patricia A., Reena S. Cecchini, Louis Fehrenbacher, et al.. (2021). NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. npj Breast Cancer. 7(1). 55–55. 9 indexed citations
4.
Rabinowits, Guilherme, Soo Jung Park, David M. Ellison, et al.. (2021). Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study.. Journal of Clinical Oncology. 39(15_suppl). 9547–9547. 8 indexed citations
5.
Awad, Mark M., Leena Gandhi, Joe Stephenson, et al.. (2016). An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 104. 126–130. 47 indexed citations
6.
7.
Newman, Walter H. & David M. Ellison. (1980). A differential effect of ouabain and β-agonists on contractility and lactic acid production in the hypertrophied heart. European Journal of Pharmacology. 68(4). 437–442. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louis Marois Breakdown of academic impact, for papers by Angelika Stein Breakdown of academic impact, for papers by Jordi Milá Breakdown of academic impact, for papers by Yasutaka Okita Breakdown of academic impact, for papers by Tassja J. Spindler Breakdown of academic impact, for papers by Matthew W. Anderson Breakdown of academic impact, for papers by Nancy L. Samberg Breakdown of academic impact, for papers by Lorien Nassi Breakdown of academic impact, for papers by Y-L. Choi Breakdown of academic impact, for papers by Stefano Vergani
Rankless by CCL
2026